中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2014年
14期
95-96
,共2页
仙灵骨葆胶囊%阿仑膦酸钠%碳酸钙D3%胸腰椎骨质疏松性骨折
仙靈骨葆膠囊%阿崙膦痠鈉%碳痠鈣D3%胸腰椎骨質疏鬆性骨摺
선령골보효낭%아륜련산납%탄산개D3%흉요추골질소송성골절
Xianlinggubao Capsule%alendronate%calcium carbonate D3%thoracolumbar osteoporotic fracture
目的：观察仙灵骨葆胶囊治疗胸腰椎骨质疏松性骨折的临床疗效。方法将胸腰椎骨质疏松性骨折患者108例随机分为观察组和对照组，各54例。对照组采用阿仑膦酸钠联合碳酸钙 D3口服治疗，观察组采用仙灵骨葆胶囊口服治疗。治疗6个月后，采用疼痛视觉模拟评分(VAS)和骨密度检查、椎体压缩楔形指数评价临床疗效，同时观察不良反应发生情况。结果观察组总有效率为96.30%，对照组为98.15%；疼痛视觉模拟评分，观察组为（1.68±0.91）分，对照组为（1.70±0.81）分；桡骨骨密度 T 值，观察组为（-2.64±0.63），对照组为（-2.41±0.57）。以上数据比较，两组差异无统计学意义（ P ﹥0.05）。治疗后，观察组椎体压缩改善程度显著大于对照组（ P ﹤0.05）；不良反应发生率，观察组为7.41%，对照组为24.07%，差异有统计学意义（ P ﹤0.05）。结论仙灵骨葆胶囊可显著提高胸腰椎骨质疏松症骨折患者的骨密度，缓解其疼痛，安全性良好，具有良好的临床疗效，值得临床推广。
目的：觀察仙靈骨葆膠囊治療胸腰椎骨質疏鬆性骨摺的臨床療效。方法將胸腰椎骨質疏鬆性骨摺患者108例隨機分為觀察組和對照組，各54例。對照組採用阿崙膦痠鈉聯閤碳痠鈣 D3口服治療，觀察組採用仙靈骨葆膠囊口服治療。治療6箇月後，採用疼痛視覺模擬評分(VAS)和骨密度檢查、椎體壓縮楔形指數評價臨床療效，同時觀察不良反應髮生情況。結果觀察組總有效率為96.30%，對照組為98.15%；疼痛視覺模擬評分，觀察組為（1.68±0.91）分，對照組為（1.70±0.81）分；橈骨骨密度 T 值，觀察組為（-2.64±0.63），對照組為（-2.41±0.57）。以上數據比較，兩組差異無統計學意義（ P ﹥0.05）。治療後，觀察組椎體壓縮改善程度顯著大于對照組（ P ﹤0.05）；不良反應髮生率，觀察組為7.41%，對照組為24.07%，差異有統計學意義（ P ﹤0.05）。結論仙靈骨葆膠囊可顯著提高胸腰椎骨質疏鬆癥骨摺患者的骨密度，緩解其疼痛，安全性良好，具有良好的臨床療效，值得臨床推廣。
목적：관찰선령골보효낭치료흉요추골질소송성골절적림상료효。방법장흉요추골질소송성골절환자108례수궤분위관찰조화대조조，각54례。대조조채용아륜련산납연합탄산개 D3구복치료，관찰조채용선령골보효낭구복치료。치료6개월후，채용동통시각모의평분(VAS)화골밀도검사、추체압축설형지수평개림상료효，동시관찰불량반응발생정황。결과관찰조총유효솔위96.30%，대조조위98.15%；동통시각모의평분，관찰조위（1.68±0.91）분，대조조위（1.70±0.81）분；뇨골골밀도 T 치，관찰조위（-2.64±0.63），대조조위（-2.41±0.57）。이상수거비교，량조차이무통계학의의（ P ﹥0.05）。치료후，관찰조추체압축개선정도현저대우대조조（ P ﹤0.05）；불량반응발생솔，관찰조위7.41%，대조조위24.07%，차이유통계학의의（ P ﹤0.05）。결론선령골보효낭가현저제고흉요추골질소송증골절환자적골밀도，완해기동통，안전성량호，구유량호적림상료효，치득림상추엄。
Objective To investigate the efficacy of Xianlinggubao Capsule in treating thoracolumbar osteoporotic fracture to provide ref-erence for clinical treatment. Methods 108 patients with thoracolumbar osteoporotic fracture in our hospital were randomly divided into the observation group and the control group 54 cases in each group. The control group used the oral administration of alendronate com-bined with calcium carbonate D3,while the observation group was given oral Xianlinggubao capsule. After 6 months of treatment,the vi-sual analogue score(VAS),bone density examination and vertebral wedge compression index were adopted to evaluate the clinical effica-cy in the two groups and the occurrence situation of adverse reactions were observed. Results The total effective rate after treatment was 96. 30% in the observation group and 98. 15% in the control group;the VAS was(1. 68 ± 0. 91)points in the observation group and(1. 70 ± 0. 81)points in the control group;the T value of radius bone density was( - 2. 64 ± 0. 63)in the observation group and ( - 2. 41 ± 0. 57)in control group,the comparison of the above data showed no statistical differences between the two groups. The verte-bral body compression degree after treatment in the observation group was significantly greater than that in the control group( P ﹥0. 05) with statistical difference between them( P ﹤ 0. 05). The occurrence rate of adverse reactions was 7. 41% in the observation group and 24. 07% in the control group with statistically significant difference between them( P ﹤ 0. 05). Conclusion Xianlinggubao Capsule can significantly increase the bone density in the patients with thoracolumbar osteoporotic fracture and alleviate their pain with good curative effect and good security,which is worthy of clinical promotion promoted in clinic.
